Literature DB >> 20691766

Extension of the neuroprotective time window for thiazolidinediones in ischemic stroke is dependent on time of reperfusion.

J Gamboa1, D A Blankenship, J P Niemi, G E Landreth, M Karl, E Hilow, S Sundararajan.   

Abstract

Stroke is a leading cause of death and disability but has limited therapeutic options. Thiazolidinediones (TZDs), agonists for the nuclear receptor, peroxisome proliferator-activated receptor (PPAR)γ, reduce infarct volume and improve neurologic function following transient middle cerebral artery occlusion (MCAO) in rats. Translation of these findings into clinical therapy will require careful assessment of dosing paradigms and effective time windows for treatment. Understanding the mechanisms by which TZDs protect the brain provides insight into how time windows for neuroprotection might be extended. We find that two TZDs, pioglitazone and rosiglitazone, significantly reduce infarct volume at doses similar to those used clinically (1 mg/kg for pioglitazone and 0.1 mg/kg for rosiglitazone). We also find that pioglitazone reduces infarction volume in a transient, but not a permanent MCAO model suggesting that reperfusion plays an important role in TZD mediated neuroprotection. Since PPARγ agonists reduce inflammation and oxidative stress, both of which are exacerbated by reperfusion, we hypothesized that TZDs would be most effective if administered prior to reperfusion. We administered TZDs 3 h after MCAO and found that infarction volume and neurologic function are significantly improved in animals reperfused at 3 h and 15 min (after TZD treatment), but not in animals reperfused at 2 h (before TZD treatment) when assessed either 24 h or 3 weeks after MCAO. While TZDs reduce intercellular adhesion molecule (ICAM) expression to a similar extent regardless of the time of reperfusion, leukocyte entry into brain parenchyma is more dramatically reduced when reperfusion is delayed until after drug treatment. The finding that delaying reperfusion until after TZD treatment is beneficial despite a longer period of ischemia, is dramatic given the widely held view that duration of ischemia is the most important determinate of injury.
Copyright © 2010 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20691766      PMCID: PMC2939146          DOI: 10.1016/j.neuroscience.2010.07.063

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  42 in total

1.  Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia.

Authors:  S Sundararajan; J L Gamboa; N A Victor; E W Wanderi; W D Lust; G E Landreth
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

Review 2.  Rosiglitazone.

Authors:  J A Balfour; G L Plosker
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

3.  Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma.

Authors:  P W Young; D R Buckle; B C Cantello; H Chapman; J C Clapham; P J Coyle; D Haigh; R M Hindley; J C Holder; H Kallender; A J Latter; K W Lawrie; D Mossakowska; G J Murphy; L Roxbee Cox; S A Smith
Journal:  J Pharmacol Exp Ther       Date:  1998-02       Impact factor: 4.030

4.  Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production.

Authors:  Jinah Hwang; Dean J Kleinhenz; Bernard Lassègue; Kathy K Griendling; Sergey Dikalov; C Michael Hart
Journal:  Am J Physiol Cell Physiol       Date:  2004-12-08       Impact factor: 4.249

5.  Attenuation of focal cerebral ischemic injury in transgenic mice overexpressing CuZn superoxide dismutase.

Authors:  H Kinouchi; C J Epstein; T Mizui; E Carlson; S F Chen; P H Chan
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

6.  Anti-ICAM-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat.

Authors:  R L Zhang; M Chopp; Y Li; C Zaloga; N Jiang; M L Jones; M Miyasaka; P A Ward
Journal:  Neurology       Date:  1994-09       Impact factor: 9.910

7.  Reperfusion following focal stroke hastens inflammation and resolution of ischemic injured tissue.

Authors:  R K Clark; E V Lee; R F White; Z L Jonak; G Z Feuerstein; F C Barone
Journal:  Brain Res Bull       Date:  1994       Impact factor: 4.077

8.  Evaluation of a motor deficit after chronic focal cerebral ischemia in rats.

Authors:  F Yonemori; T Yamaguchi; H Yamada; A Tamura
Journal:  J Cereb Blood Flow Metab       Date:  1998-10       Impact factor: 6.200

9.  Reversible middle cerebral artery occlusion without craniectomy in rats.

Authors:  E Z Longa; P R Weinstein; S Carlson; R Cummins
Journal:  Stroke       Date:  1989-01       Impact factor: 7.914

10.  Reversible middle cerebral artery occlusion in rats using an intraluminal thread technique.

Authors:  S Kawamura; Y Li; M Shirasawa; N Yasui; H Fukasawa
Journal:  Surg Neurol       Date:  1994-05
View more
  9 in total

1.  XQ-1H Suppresses Neutrophils Infiltration and Oxidative Stress Induced by Cerebral Ischemia Injury Both In Vivo and In Vitro.

Authors:  Jie Wei; Weirong Fang; Lan Sha; Dan Han; Rui Zhang; Xin Hao; Yunman Li
Journal:  Neurochem Res       Date:  2013-10-12       Impact factor: 3.996

2.  T33, a novel peroxisome proliferator-activated receptor γ/α agonist, exerts neuroprotective action via its anti-inflammatory activities.

Authors:  Ying Wang; Yu-she Yang; Xi-can Tang; Hai-yan Zhang
Journal:  Acta Pharmacol Sin       Date:  2011-08-01       Impact factor: 6.150

3.  KLF11 mediates PPARγ cerebrovascular protection in ischaemic stroke.

Authors:  Ke-Jie Yin; Yanbo Fan; Milton Hamblin; Jifeng Zhang; Tainqing Zhu; Siming Li; John R Hawse; Malayannan Subramaniam; Chao-Zhong Song; Raul Urrutia; Jiandie D Lin; Y Eugene Chen
Journal:  Brain       Date:  2013-02-12       Impact factor: 13.501

4.  Method parameters' impact on mortality and variability in rat stroke experiments: a meta-analysis.

Authors:  Jakob O Ström; Edvin Ingberg; Annette Theodorsson; Elvar Theodorsson
Journal:  BMC Neurosci       Date:  2013-04-01       Impact factor: 3.288

5.  New insights into the role of peroxisome proliferator-activated receptors in regulating the inflammatory response after tissue injury.

Authors:  Miriam D Neher; Sebastian Weckbach; Markus S Huber-Lang; Philip F Stahel
Journal:  PPAR Res       Date:  2012-02-29       Impact factor: 4.964

6.  Rosiglitazone increases cerebral klotho expression to reverse baroreflex in type 1-like diabetic rats.

Authors:  Li-Jen Chen; Meng-Fu Cheng; Po-Ming Ku; Jia-Wei Lin
Journal:  Biomed Res Int       Date:  2014-02-13       Impact factor: 3.411

7.  Peroxisome proliferator-activated receptor-gamma dependent pathway reduces the phosphorylation of dynamin-related protein 1 and ameliorates hippocampal injury induced by global ischemia in rats.

Authors:  Yao-Chung Chuang; Tsu-Kung Lin; Ding-I Yang; Jenq-Lin Yang; Chia-Wei Liou; Shang-Der Chen
Journal:  J Biomed Sci       Date:  2016-05-12       Impact factor: 8.410

Review 8.  Diverse roles of mitochondria in ischemic stroke.

Authors:  Jenq-Lin Yang; Sujira Mukda; Shang-Der Chen
Journal:  Redox Biol       Date:  2018-03-09       Impact factor: 11.799

9.  Chronic Low-Dose Alcohol Consumption Attenuates Post-Ischemic Inflammation via PPARγ in Mice.

Authors:  Chun Li; Jiyu Li; Ethyn G Loreno; Sumitra Miriyala; Manikandan Panchatcharam; Xiaohong Lu; Hong Sun
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.